NCT03493568 - Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE) | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

February 6, 2017

Primary Completion Date

March 20, 2018

Study Completion Date

July 31, 2020

Conditions

HIV-1-infection

Interventions

DRUG

Genvoya 150Mg-150Mg-200Mg-10Mg Tablet

switch to Genvoya 150Mg-150Mg-200Mg-10Mg Tablet in patients virologically suppressed HIV-1 infected patients.

DRUG

Dolutegravir 50 mg plus one RTI

Continuing Dolutegravir 50 mg (1 pill every 24 hours) plus one RTI (at label dose)

Trial Locations (2)

Ospedale San Raffaele, Milan

Ospedale San Raffaele Scientific Institute, Milan